Erythropoietin - Dong-A ST

Drug Profile

Erythropoietin - Dong-A ST

Alternative Names: DA-3285; EPO - Dong-A ST; Eporon; Erythropoietin - Dong-A; Erythropoietin alfa

Latest Information Update: 18 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dem Ilac; Dong-A Pharmaceutical
  • Class Antianaemics; Recombinant erythropoietins; Recombinant fusion proteins
  • Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 03 Feb 2016 Dong-A ST and Ajou University School of Medicine plan the phase II NIMBUS trial for Stroke in South Korea (IV) (NCT02603406)
  • 03 Feb 2016 Dong-A ST plans a pharmacokinetics/pharmacodynamics phase I trial in Healthy male volunteers in South Korea (SC) (NCT02580006)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top